Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for
various cerebral proteopathies. Here we leverage the unique characteristics of the …

To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease,, supportive …

Although the prevalence of dementia continues to increase worldwide, incidence in the
western world might have decreased as a result of better vascular care and improved brain …

During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD)
considering the disease as a continuum. Thanks to evolving biomarker research and …

Alzheimer's disease causes a progressive dementia that currently affects over 35 million
individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no …

Abstract" Serum ferritin" presents a paradox, as the iron storage protein ferritin is not
synthesised in serum yet is to be found there. Serum ferritin is also a well known …

In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …

Objective To perform a systematic review and meta-analysis to determine whether fluid and
imaging astrocyte biomarkers are altered in Alzheimer disease (AD). Methods PubMed and …